{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:10:41Z","timestamp":1791951041447,"version":"4.3.4"},"reference-count":166,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2020.00149","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T04:51:26Z","timestamp":1588654286000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":69,"title":["Pediatric Cholestatic Liver Disease: Review of Bile Acid Metabolism and Discussion of Current and Emerging Therapies"],"prefix":"10.3389","volume":"7","author":[{"given":"Alyssa","family":"Kriegermeier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/ajt.15276","article-title":"OPTN\/SRTR 2017 annual data report: liver","volume":"19","author":"Kim","year":"2019","journal-title":"Am J Transplant."},{"key":"B2","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jhep.2017.04.026","article-title":"Biliary bile acids in hepatobiliary injury - what is the link?","volume":"67","author":"Fickert","year":"2017","journal-title":"J Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1432-1033.1967.tb00103.x","article-title":"Effect of biliary drainage on individual reactions in the conversion of cholesterol to taurochlic acid. Bile acids and steroids 180","volume":"2","author":"Danielsson","year":"1967","journal-title":"Eur J Biochem."},{"key":"B4","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0022-2275(20)43099-8","article-title":"7-alpha-hydroxylation of cholestanol by rat liver microsomes","volume":"9","author":"Shefer","year":"1968","journal-title":"J Lipid Res"},{"key":"B5","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0022-2275(20)41612-8","article-title":"Mechanism of degradation of the steroid side chain in the formation of bile acids","volume":"33","author":"Bjorkhem","year":"1992","journal-title":"J Lipid Res."},{"key":"B6","doi-asserted-by":"crossref","first-page":"21319","DOI":"10.1016\/S0021-9258(19)36611-6","article-title":"Purification and characterization of 7 alpha-hydroxy-4-cholesten-3-one 12 alpha-hydroxylase","volume":"267","author":"Ishida","year":"1992","journal-title":"J Biol Chem."},{"key":"B7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1203\/00006450-198702000-00017","article-title":"Biliary bile acid composition of the human fetus in early gestation","volume":"21","author":"Colombo","year":"1987","journal-title":"Pediatr Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/0009-8981(59)90030-0","article-title":"On the bile acids in duodenal contents of infants and children. Bile acids and steroids 72","volume":"4","author":"Encrantz","year":"1959","journal-title":"Clin Chim Acta."},{"key":"B9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0006-291X(86)90261-5","article-title":"Conjugation of cholic acid with taurine and glycine by rat liver peroxisomes","volume":"138","author":"Kase","year":"1986","journal-title":"Biochem Biophys Res Commun."},{"key":"B10","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.cld.2018.06.006","article-title":"Inborn errors of bile acid metabolism","volume":"22","author":"Heubi","year":"2018","journal-title":"Clin Liver Dis."},{"key":"B11","doi-asserted-by":"crossref","first-page":"16637","DOI":"10.1016\/S0021-9258(18)37438-6","article-title":"Hepatic bile acid metabolism during early development revealed from the analysis of human fetal gallbladder bile","volume":"263","author":"Setchell","year":"1988","journal-title":"J Biol Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.3181\/00379727-100-24741","article-title":"Dietary glycine and taurine on bile acid conjugation in man; bile acids and steroids 75","volume":"100","author":"Sjovall","year":"1959","journal-title":"Proc Soc Exp Biol Med."},{"key":"B13","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S0022-2275(20)37196-0","article-title":"Cloning, expression, and chromosomal localization of mouse liver bile acid CoA:amino acid N-acyltransferase","volume":"38","author":"Falany","year":"1997","journal-title":"J Lipid Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1021\/acschembio.7b00865","article-title":"Bile acid recognition by mouse ileal bile acid binding protein","volume":"12","author":"Badiee","year":"2017","journal-title":"ACS Chem Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.bbadis.2018.05.011","article-title":"Animal models to study bile acid metabolism","volume":"1865","author":"Li","year":"2019","journal-title":"Biochim Biophys Acta Mol Basis Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/3034","article-title":"A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis","volume":"20","author":"Strautnieks","year":"1998","journal-title":"Nat Genet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/0016-5085(86)90859-0","article-title":"Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents","volume":"90","author":"Yoon","year":"1986","journal-title":"Gastroenterology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/hep.20943","article-title":"Novel biotransformation and physiological properties of norursodeoxycholic acid in humans","volume":"42","author":"Hofmann","year":"2005","journal-title":"Hepatology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/hep.20653","article-title":"Secretin activation of the apical Na+-dependent bile acid transporter is associated with cholehepatic shunting in rats","volume":"41","author":"Alpini","year":"2005","journal-title":"Hepatology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1002\/hep.22891","article-title":"Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2\u2013\/\u2013 mice","volume":"49","author":"Halilbasic","year":"2009","journal-title":"Hepatology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1002\/hep.510230435","article-title":"Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis","volume":"23","author":"Deleuze","year":"1996","journal-title":"Hepatology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/0092-8674(93)90380-9","article-title":"Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease","volume":"75","author":"Smit","year":"1993","journal-title":"Cell."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/hep.26424","article-title":"Genotype-phenotype relationships in the low-phospholipid-associated cholelithiasis syndrome: a study of 156 consecutive patients","volume":"58","author":"Poupon","year":"2013","journal-title":"Hepatology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.dld.2007.10.016","article-title":"Hepatobiliary phospholipid transporter ABCB4, MDR3 gene variants in a large cohort of Italian women with intrahepatic cholestasis of pregnancy","volume":"40","author":"Floreani","year":"2008","journal-title":"Dig Liver Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/ng0398-219","article-title":"A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis","volume":"18","author":"Bull","year":"1998","journal-title":"Nat Genet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1126\/science.272.5267.1495","article-title":"A subfamily of P-type ATPases with aminophospholipid transporting activity","volume":"272","author":"Tang","year":"1996","journal-title":"Science."},{"key":"B27","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1053\/j.gastro.2003.12.013","article-title":"Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity","volume":"126","author":"Chen","year":"2004","journal-title":"Gastroenterology."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1126\/science.290.5497.1771","article-title":"Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters","volume":"290","author":"Berge","year":"2000","journal-title":"Science."},{"key":"B29","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1053\/j.gastro.2005.10.022","article-title":"Liver transplantation in a patient with sitosterolemia and cirrhosis","volume":"130","author":"Miettinen","year":"2006","journal-title":"Gastroenterology."},{"key":"B30","doi-asserted-by":"publisher","first-page":"G165","DOI":"10.1152\/ajpgi.00362.2002","article-title":"A common dubin-Johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2)","volume":"284","author":"Keitel","year":"2003","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1172\/JCI59526","article-title":"Complete OATP1B1 and OATP1B3 deficiency causes human rotor syndrome by interrupting conjugated bilirubin reuptake into the liver","volume":"122","author":"van de Steeg","year":"2012","journal-title":"J Clin Invest."},{"key":"B32","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1152\/ajpgi.1996.270.1.G1","article-title":"Bile duct epithelium: frontiers in transport physiology","volume":"270","author":"Boyer","year":"1996","journal-title":"Am J Physiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/cphy.c120027","article-title":"Bile formation and secretion","volume":"3","author":"Boyer","year":"2013","journal-title":"Compr Physiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1053\/j.gastro.2008.02.020","article-title":"Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis","volume":"134","author":"Salas","year":"2008","journal-title":"Gastroenterology."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1086\/340448","article-title":"PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin-transcription-factor domains and parallel beta-helix 1 repeats","volume":"70","author":"Onuchic","year":"2002","journal-title":"Am J Hum Genet."},{"key":"B36","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1136\/gut.9.1.22","article-title":"Degradation of bile salts by human intestinal bacteria","volume":"9","author":"Hill","year":"1968","journal-title":"Gut."},{"key":"B37","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1017\/CBO9780511547409.033","article-title":"Disorders of bile acid synthesis and metabolism: a metabolic basis for liver disease","volume-title":"Liver Disease in Children","author":"Setchell","year":"2007"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/S0016-5085(79)80079-7","article-title":"Transformation of chenodeoxycholic acid and ursodeoxycholic acid by human intestinal bacteria","volume":"77","author":"Fedorowski","year":"1979","journal-title":"Gastroenterology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1194\/jlr.M200478-JLR200","article-title":"Effect of ursodeoxycholic acid on cholesterol absorption and metabolism in humans","volume":"44","author":"Woollett","year":"2003","journal-title":"J Lipid Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1152\/physrev.00027.2002","article-title":"Bile salt transporters: molecular characterization, function, and regulation","volume":"83","author":"Trauner","year":"2003","journal-title":"Physiol Rev."},{"key":"B41","doi-asserted-by":"publisher","first-page":"66S","DOI":"10.1002\/hep.1840040812","article-title":"Bile acids and bile salts: ionization and solubility properties","volume":"4","author":"Carey","year":"1984","journal-title":"Hepatology."},{"key":"B42","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1146\/annurev.me.18.020167.002001","article-title":"Detergent properties of bile salts: correlation with physiological function","volume":"18","author":"Hofmann","year":"1967","journal-title":"Annu Rev Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"27228","DOI":"10.1074\/jbc.270.45.27228","article-title":"Identification of a mutation in the ileal sodium-dependent bile acid transporter gene that abolishes transport activity","volume":"270","author":"Wong","year":"1995","journal-title":"J Biol Chem."},{"key":"B44","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1006\/geno.1996.0233","article-title":"Localization of the ileal sodium-bile acid cotransporter gene (SLC10A2) to human chromosome 13q33","volume":"33","author":"Wong","year":"1996","journal-title":"Genomics."},{"key":"B45","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1073\/pnas.91.11.4741","article-title":"Molecular cloning, tissue distribution, and expression of a 14-kDa bile acid-binding protein from rat ileal cytosol","volume":"91","author":"Gong","year":"1994","journal-title":"Proc Natl Acad Sci USA."},{"key":"B46","doi-asserted-by":"publisher","first-page":"G1124","DOI":"10.1152\/ajpgi.00539.2005","article-title":"Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents","volume":"290","author":"Boyer","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1172\/JCI117091","article-title":"Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+\/bile acid cotransporter","volume":"93","author":"Hagenbuch","year":"1994","journal-title":"J Clin Invest."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1002\/hep.29251","article-title":"Hepatic uptake of conjugated bile acids is mediated by both sodium taurocholate cotransporting polypeptide and organic anion transporting polypeptides and modulated by intestinal sensing of plasma bile acid levels in mice","volume":"66","author":"Slijepcevic","year":"2017","journal-title":"Hepatology."},{"key":"B49","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.bbamcr.2006.04.014","article-title":"Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration","volume":"1773","author":"Geier","year":"2007","journal-title":"Biochim Biophys Acta."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1194\/jlr.R054114","article-title":"Intestinal transport and metabolism of bile acids","volume":"56","author":"Dawson","year":"2015","journal-title":"J Lipid Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bile acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","article-title":"Bile acids: natural ligands for an orphan nuclear receptor","volume":"284","author":"Parks","year":"1999","journal-title":"Science."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1126\/science.272.5266.1336","article-title":"An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors","volume":"272","author":"Seol","year":"1996","journal-title":"Science."},{"key":"B54","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","article-title":"Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR","volume":"3","author":"Wang","year":"1999","journal-title":"Mol Cell."},{"key":"B55","doi-asserted-by":"publisher","first-page":"10713","DOI":"10.1038\/ncomms10713","article-title":"Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis","volume":"7","author":"Gomez-Ospina","year":"2016","journal-title":"Nat Commun."},{"key":"B56","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Mol Cell."},{"key":"B57","doi-asserted-by":"publisher","first-page":"27277","DOI":"10.1074\/jbc.M704244200","article-title":"Liver-specific activities of FGF19 require klotho beta","volume":"282","author":"Lin","year":"2007","journal-title":"J Biol Chem."},{"key":"B58","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab."},{"key":"B59","doi-asserted-by":"publisher","first-page":"19909","DOI":"10.1074\/jbc.M207903200","article-title":"Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter","volume":"278","author":"Chen","year":"2003","journal-title":"J Biol Chem."},{"key":"B60","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1053\/gast.2001.25503","article-title":"The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp","volume":"121","author":"Denson","year":"2001","journal-title":"Gastroenterology."},{"key":"B61","doi-asserted-by":"publisher","first-page":"28857","DOI":"10.1074\/jbc.M011610200","article-title":"Human bile salt export pump promoter is transactivated by the farnesoid X receptor\/bile acid receptor","volume":"276","author":"Ananthanarayanan","year":"2001","journal-title":"J Biol Chem."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1172\/JCI18945","article-title":"Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis","volume":"112","author":"Liu","year":"2003","journal-title":"J Clin Invest."},{"key":"B63","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1172\/JCI42846","article-title":"Combined deletion of Fxr and Shp in mice induces Cyp17a1 and results in juvenile onset cholestasis","volume":"121","author":"Anakk","year":"2011","journal-title":"J Clin Invest."},{"key":"B64","doi-asserted-by":"publisher","first-page":"614","DOI":"10.2174\/138920008785821666","article-title":"New insights on the xenobiotic-sensing nuclear receptors in liver diseases\u2013CAR and PXR","volume":"9","author":"Kakizaki","year":"2008","journal-title":"Curr Drug Metab."},{"key":"B65","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1073\/pnas.051551698","article-title":"The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity","volume":"98","author":"Staudinger","year":"2001","journal-title":"Proc Natl Acad Sci USA."},{"key":"B66","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1073\/pnas.051014398","article-title":"An essential role for nuclear receptors SXR\/PXR in detoxification of cholestatic bile acids","volume":"98","author":"Xie","year":"2001","journal-title":"Proc Natl Acad Sci USA."},{"key":"B67","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S0006-291X(02)02550-0","article-title":"Identification of membrane-type receptor for bile acids (M-BAR)","volume":"298","author":"Maruyama","year":"2002","journal-title":"Biochem Biophys Res Commun."},{"key":"B68","doi-asserted-by":"publisher","first-page":"9435","DOI":"10.1074\/jbc.M209706200","article-title":"A G protein-coupled receptor responsive to bile acids","volume":"278","author":"Kawamata","year":"2003","journal-title":"J Biol Chem."},{"key":"B69","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/164_2019_238","article-title":"The pharmacology of bile acids and their receptors","volume":"256","author":"Fiorucci","year":"2019","journal-title":"Handb Exp Pharmacol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/hep.21458","article-title":"The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells","volume":"45","author":"Keitel","year":"2007","journal-title":"Hepatology."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.3389\/fimmu.2018.01853","article-title":"Bile acids activated receptors regulate innate immunity","volume":"9","author":"Fiorucci","year":"2018","journal-title":"Front Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1172\/JCI64551","article-title":"The TGR5 receptor mediates bile acid-induced itch and analgesia","volume":"123","author":"Alemi","year":"2013","journal-title":"J Clin Invest."},{"key":"B73","doi-asserted-by":"publisher","first-page":"11055","DOI":"10.1074\/jbc.M117.784322","article-title":"Farnesoid X receptor induces takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism","volume":"292","author":"Pathak","year":"2017","journal-title":"J Biol Chem."},{"key":"B74","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/164_2019_236","article-title":"Bile acid-activated receptors: a review on FXR and other nuclear receptors","volume":"256","author":"Shin","year":"2019","journal-title":"Handb Exp Pharmacol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jhep.2010.11.005","article-title":"Endoplasmic reticulum stress in liver disease","volume":"54","author":"Malhi","year":"2011","journal-title":"J Hepatol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"G498","DOI":"10.1152\/ajpgi.00482.2007","article-title":"CHOP deficiency attenuates cholestasis-induced liver fibrosis by reduction of hepatocyte injury","volume":"294","author":"Tamaki","year":"2008","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/hep.29815","article-title":"Farnesoid X receptor signaling activates the hepatic X-box binding protein 1 pathway in vitro and in mice","volume":"68","author":"Liu","year":"2018","journal-title":"Hepatology."},{"key":"B78","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jcmgh.2016.11.006","article-title":"Endoplasmic reticulum stress regulates hepatic bile acid metabolism in mice","volume":"3","author":"Henkel","year":"2017","journal-title":"Cell Mol Gastroenterol Hepatol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1194\/jlr.M071266","article-title":"Hepatic deletion of X-box binding protein 1 impairs bile acid metabolism in mice","volume":"58","author":"Liu","year":"2017","journal-title":"J Lipid Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"e607","DOI":"10.1542\/peds.2011-1423","article-title":"Efficacy of fat-soluble vitamin supplementation in infants with biliary atresia","volume":"130","author":"Shneider","year":"2012","journal-title":"Pediatrics."},{"key":"B81","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/MPG.0b013e31825c9732","article-title":"Oral absorbable fat-soluble vitamin formulation in pediatric patients with cholestasis","volume":"55","author":"Shen","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"B82","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology."},{"key":"B83","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/hep.1840150409","article-title":"Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease","volume":"15","author":"Beuers","year":"1992","journal-title":"Hepatology."},{"key":"B84","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J Hepatol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1053\/j.gastro.2005.05.009","article-title":"Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans","volume":"129","author":"Marschall","year":"2005","journal-title":"Gastroenterology."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1053\/j.gastro.2007.08.071","article-title":"Ursodeoxycholic acid stimulates cholangiocyte fluid secretion in mice via CFTR-dependent ATP secretion","volume":"133","author":"Fiorotto","year":"2007","journal-title":"Gastroenterology."},{"key":"B87","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/hep.29804","article-title":"Bile acids stimulate cholangiocyte fluid secretion by activation of transmembrane member 16A Cl(-) channels","volume":"68","author":"Li","year":"2018","journal-title":"Hepatology."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1172\/JCI1325","article-title":"A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation","volume":"101","author":"Rodrigues","year":"1998","journal-title":"J Clin Invest."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1194\/jlr.R900011-JLR200","article-title":"Bile acids: regulation of apoptosis by ursodeoxycholic acid","volume":"50","author":"Amaral","year":"2009","journal-title":"J Lipid Res."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1126\/science.1128294","article-title":"Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes","volume":"313","author":"Ozcan","year":"2006","journal-title":"Science."},{"key":"B91","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.1840160213","article-title":"Immunomodulatory effects of ursodeoxycholic acid on immune responses","volume":"16","author":"Yoshikawa","year":"1992","journal-title":"Hepatology."},{"key":"B92","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/0006-291X(92)91146-H","article-title":"Ursodeoxycholic acid-dependent activation of the glucocorticoid receptor","volume":"188","author":"Tanaka","year":"1992","journal-title":"Biochem Biophys Res Commun."},{"key":"B93","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/hep.1840160315","article-title":"Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial","volume":"16","author":"Beuers","year":"1992","journal-title":"Hepatology."},{"key":"B94","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/hep.1840140516","article-title":"Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study","volume":"14","author":"O'Brien","year":"1991","journal-title":"Hepatology."},{"key":"B95","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3109\/00365529409103626","article-title":"Ursodeoxycholic acid therapy in treatment of primary sclerosing cholangitis","volume":"204","author":"Stiehl","year":"1994","journal-title":"Scand J Gastroenterol Suppl."},{"key":"B96","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1056\/NEJM199703063361003","article-title":"Ursodiol for primary sclerosing cholangitis. Mayo primary sclerosing cholangitis-ursodeoxycholic acid study group","volume":"336","author":"Lindor","year":"1997","journal-title":"N Engl J Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology."},{"key":"B98","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/hep.23294","article-title":"Diagnosis and management of primary sclerosing cholangitis","volume":"51","author":"Chapman","year":"2010","journal-title":"Hepatology."},{"key":"B99","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/00005176-200008000-00009","article-title":"Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children","volume":"31","author":"Gilger","year":"2000","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B100","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1053\/jhep.2003.50289","article-title":"Primary sclerosing cholangitis in children: a long-term follow-up study","volume":"38","author":"Feldstein","year":"2003","journal-title":"Hepatology."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1002\/hep4.1251","article-title":"Gamma glutamyltransferase reduction is associated with favorable outcomes in pediatric primary sclerosing cholangitis","volume":"2","author":"Deneau","year":"2018","journal-title":"Hepatol Commun."},{"key":"B102","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jpeds.2019.01.039","article-title":"Ursodeoxycholic acid therapy in pediatric primary sclerosing cholangitis: predictors of gamma glutamyltransferase normalization and favorable clinical course","volume":"209","author":"Deneau","year":"2019","journal-title":"J Pediatr."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1002\/hep4.1421","article-title":"A prospective trial of withdrawal and reinstitution of ursodeoxycholic acid in pediatric primary sclerosing cholangitis","volume":"3","author":"Black","year":"2019","journal-title":"Hepatol Commun."},{"key":"B104","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jhep.2009.11.012","article-title":"Liver disease associated with canalicular transport defects: current and future therapies","volume":"52","author":"Stapelbroek","year":"2010","journal-title":"J Hepatol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"CD000222","DOI":"10.1002\/14651858.CD000222.pub4","article-title":"Ursodeoxycholic acid for cystic fibrosis-related liver disease","volume":"9","author":"Cheng","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"key":"B106","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0022-2275(20)38445-5","article-title":"Synthesis of 24-nor-5 beta-cholan-23-oic acid derivatives: a convenient and efficient one-carbon degradation of the side chain of natural bile acids","volume":"29","author":"Schteingart","year":"1988","journal-title":"J Lipid Res."},{"key":"B107","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1053\/j.gastro.2005.10.018","article-title":"24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice","volume":"130","author":"Fickert","year":"2006","journal-title":"Gastroenterology"},{"key":"B108","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jceh.2014.02.001","article-title":"Protective effects of norursodeoxycholic acid versus ursodeoxycholic acid on thioacetamide-induced rat liver fibrosis","volume":"4","author":"Buko","year":"2014","journal-title":"J Clin Exp Hepatol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"e0200897","DOI":"10.1371\/journal.pone.0200897","article-title":"NorUDCA promotes degradation of alpha1-antitrypsin mutant Z protein by inducing autophagy through AMPK\/ULK1 pathway","volume":"13","author":"Tang","year":"2018","journal-title":"PLoS ONE."},{"key":"B110","doi-asserted-by":"publisher","first-page":"G156","DOI":"10.1152\/ajpgi.00143.2015","article-title":"Autophagy induced by exogenous bile acids is therapeutic in a model of alpha-1-AT deficiency liver disease","volume":"311","author":"Tang","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J Hepatol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/MPG.0000000000001657","article-title":"Oral cholic acid is efficacious and well tolerated in patients with bile acid synthesis and zellweger spectrum disorders","volume":"65","author":"Heubi","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"B113","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1097\/01.mpg.0000226386.79483.7b","article-title":"Defects in bile acid biosynthesis\u2013diagnosis and treatment","volume":"43","author":"Setchell","year":"2006","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"B114","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/00005176-199910000-00013","article-title":"Use of rifampin for severe pruritus in children with chronic cholestasis","volume":"29","author":"Yerushalmi","year":"1999","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/0016-5085(90)90027-X","article-title":"Rifampin relieves pruritus in children with cholestatic liver disease","volume":"98","author":"Cynamon","year":"1990","journal-title":"Gastroenterology."},{"key":"B116","doi-asserted-by":"publisher","first-page":"307","DOI":"10.5414\/CPP42307","article-title":"Influence of rifampin on serum markers of cholesterol and bile acid synthesis in men","volume":"42","author":"Lutjohann","year":"2004","journal-title":"Int J Clin Pharmacol Ther."},{"key":"B117","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1128\/AAC.19.2.342","article-title":"Effects of rifampin on biliary lipids in humans","volume":"19","author":"von Bergmann","year":"1981","journal-title":"Antimicrob Agents Chemother."},{"key":"B118","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/gut.50.3.436","article-title":"Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis","volume":"50","author":"Prince","year":"2002","journal-title":"Gut."},{"key":"B119","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41575-019-0132-z","article-title":"Neonatal cholestasis: emerging molecular diagnostics and potential novel therapeutics","volume":"16","author":"Feldman","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/CE.S26725","article-title":"Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action","volume":"7","author":"Zema","year":"2012","journal-title":"Core Evid."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1136\/gutjnl-2017-314553","article-title":"Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2(\u2013\/\u2013) mice by modulating composition, signalling and excretion of faecal bile acids","volume":"67","author":"Fuchs","year":"2018","journal-title":"Gut."},{"key":"B122","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4161\/pri.28938","article-title":"The therapeutic potential of chemical chaperones in protein folding diseases","volume":"8","author":"Cortez","year":"2014","journal-title":"Prion."},{"key":"B123","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.cbi.2015.09.025","article-title":"4-PBA prevents pressure overload-induced myocardial hypertrophy and interstitial fibrosis by attenuating endoplasmic reticulum stress","volume":"242","author":"Luo","year":"2015","journal-title":"Chem Biol Interact."},{"key":"B124","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.toxlet.2017.02.023","article-title":"4-PBA inhibits LPS-induced inflammation through regulating ER stress and autophagy in acute lung injury models","volume":"271","author":"Zeng","year":"2017","journal-title":"Toxicol Lett"},{"key":"B125","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.tox.2017.01.002","article-title":"Pyrazinamide-induced hepatotoxicity is alleviated by 4-PBA via inhibition of the PERK-eIF2alpha-ATF4-CHOP pathway","volume":"378","author":"Guo","year":"2017","journal-title":"Toxicology."},{"key":"B126","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/hep.27767","article-title":"Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: evidence for improvement of cholestasis with 4-phenylbutyrate","volume":"62","author":"Gonzales","year":"2015","journal-title":"Hepatology."},{"key":"B127","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/hep.23268","article-title":"Folding defects in P-type ATP 8B1 associated with hereditary cholestasis are ameliorated by 4-phenylbutyrate","volume":"51","author":"van der Velden","year":"2010","journal-title":"Hepatology."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1002\/hep.21630","article-title":"4-phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumps","volume":"45","author":"Hayashi","year":"2007","journal-title":"Hepatology."},{"key":"B129","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1750-1172-9-89","article-title":"Intractable itch relieved by 4-phenylbutyrate therapy in patients with progressive familial intrahepatic cholestasis type 1","volume":"9","author":"Hasegawa","year":"2014","journal-title":"Orphanet J Rare Dis."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.jpeds.2013.12.032","article-title":"Improved liver function and relieved pruritus after 4-phenylbutyrate therapy in a patient with progressive familial intrahepatic cholestasis type 2","volume":"164","author":"Naoi","year":"2014","journal-title":"J Pediatr."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1073\/pnas.97.4.1796","article-title":"Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: a potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency","volume":"97","author":"Burrows","year":"2000","journal-title":"Proc Natl Acad Sci USA."},{"key":"B132","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/00005176-200407000-00007","article-title":"Lack of effect of oral 4-phenylbutyrate on serum alpha-1-antitrypsin in patients with alpha-1-antitrypsin deficiency: a preliminary study","volume":"39","author":"Teckman","year":"2004","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.jhep.2016.02.001","article-title":"Rescue of defective ATP8B1 trafficking by CFTR correctors as a therapeutic strategy for familial intrahepatic cholestasis","volume":"64","author":"van der Woerd","year":"2016","journal-title":"J Hepatol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4306\/pi.2016.13.5.580","article-title":"Bipolar and related disorders induced by sodium 4-phenylbutyrate in a male adolescent with bile salt export pump deficiency disease","volume":"13","author":"Vitale","year":"2016","journal-title":"Psychiatry Investig."},{"key":"B135","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/MPG.0000000000001082","article-title":"Possible phenylacetate hepatotoxicity during 4-phenylbutyrate therapy of byler disease","volume":"62","author":"Shneider","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"B136","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/hep.27973","article-title":"Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice","volume":"63","author":"Miethke","year":"2016","journal-title":"Hepatology."},{"key":"B137","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jhep.2015.10.024","article-title":"Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis","volume":"64","author":"Baghdasaryan","year":"2016","journal-title":"J Hepatol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","article-title":"Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study","volume":"389","author":"Hegade","year":"2017","journal-title":"Lancet."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/hep4.1244","article-title":"Placebo-controlled randomized trial of an intestinal bile salt transport inhibitor for pruritus in alagille syndrome","volume":"2","author":"Shneider","year":"2018","journal-title":"Hepatol Commun."},{"key":"B140","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1021\/jm0002127","article-title":"Identification of a chemical tool for the orphan nuclear receptor FXR","volume":"43","author":"Maloney","year":"2000","journal-title":"J Med Chem."},{"key":"B141","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J Med Chem"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology."},{"key":"B143","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med."},{"key":"B144","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/hep.24537","article-title":"Dual farnesoid X receptor\/TGR5 agonist INT-767 reduces liver injury in the Mdr2\u2013\/\u2013 (Abcb4\u2013\/\u2013) mouse cholangiopathy model by promoting biliary HCO(-)(3) output","volume":"54","author":"Baghdasaryan","year":"2011","journal-title":"Hepatology."},{"key":"B146","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology."},{"key":"B147","doi-asserted-by":"publisher","first-page":"172661","DOI":"10.1016\/j.ejphar.2019.172661","article-title":"Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis","volume":"863","author":"Venetsanaki","year":"2019","journal-title":"Eur J Pharmacol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"9960","DOI":"10.1021\/acs.jmedchem.7b00907","article-title":"Discovery of tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH)","volume":"60","author":"Tully","year":"2017","journal-title":"J Med Chem."},{"key":"B149","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/S0002-9440(10)61177-7","article-title":"A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice","volume":"160","author":"Nicholes","year":"2002","journal-title":"Am J Pathol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1158\/0008-5472.CAN-14-0208","article-title":"Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19","volume":"74","author":"Zhou","year":"2014","journal-title":"Cancer Res."},{"key":"B151","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J Hepatol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/MPG.0000000000002256","article-title":"A phase I\/IIa trial of intravenous immunoglobulin following portoenterostomy in biliary atresia","volume":"68","author":"Mack","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1001\/jama.2014.2623","article-title":"Use of corticosteroids after hepatoportoenterostomy for bile drainage in infants with biliary atresia: the START randomized clinical trial","volume":"311","author":"Bezerra","year":"2014","journal-title":"JAMA."},{"key":"B154","doi-asserted-by":"publisher","first-page":"e0158156","DOI":"10.1371\/journal.pone.0158156","article-title":"Antifibrotic effects of the dual CCR2\/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis","volume":"11","author":"Lefebvre","year":"2016","journal-title":"PLoS ONE."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1053\/gast.2000.20222","article-title":"Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis","volume":"119","author":"De Vree","year":"2000","journal-title":"Gastroenterology."},{"key":"B156","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/TP.0000000000000463","article-title":"Improvement of hepatocyte transplantation efficiency in the mdr2\u2013\/\u2013 mouse model by glyceryl trinitrate","volume":"99","author":"Boudechiche","year":"2015","journal-title":"Transplantation."},{"key":"B157","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1111\/j.1582-4934.2012.01586.x","article-title":"Hepatocyte transplantation in bile salt export pump-deficient mice: selective growth advantage of donor hepatocytes under bile acid stress","volume":"16","author":"Chen","year":"2012","journal-title":"J Cell Mol Med."},{"key":"B158","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10545-006-0245-8","article-title":"Hepatocyte transplantation for liver-based metabolic disorders","volume":"29","author":"Dhawan","year":"2006","journal-title":"J Inherit Metab Dis."},{"key":"B159","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.3727\/096368908787648083","article-title":"Liver after hepatocyte transplantation for liver-based metabolic disorders in children","volume":"17","author":"Quaglia","year":"2008","journal-title":"Cell Transplant."},{"key":"B160","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/pr.2017.284","article-title":"Human hepatocyte transplantation for liver disease: current status and future perspectives","volume":"83","author":"Iansante","year":"2018","journal-title":"Pediatr Res."},{"key":"B161","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s40472-017-0165-6","article-title":"Clinical hepatocyte transplantation: what is next?","volume":"4","author":"Squires","year":"2017","journal-title":"Curr Transplant Rep."},{"key":"B162","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.3892\/mmr.2018.9353","article-title":"Antifibrotic potential of bone marrowderived mesenchymal stem cells in biliary atresia mice","volume":"18","author":"Lei","year":"2018","journal-title":"Mol Med Rep."},{"key":"B163","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.transproceed.2008.03.110","article-title":"Management of hyperbilirubinemia in biliary atresia by hepatic progenitor cell transplantation through hepatic artery: a case report","volume":"40","author":"Khan","year":"2008","journal-title":"Transplant Proc."},{"key":"B164","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00383-010-2712-4","article-title":"Bone marrow mononuclear stem cell infusion improves biochemical parameters and scintigraphy in infants with biliary atresia","volume":"27","author":"Sharma","year":"2011","journal-title":"Pediatr Surg Int."},{"key":"B165","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3390\/biomedicines4010002","article-title":"Stem cell therapies for treatment of liver disease","volume":"4","author":"Nicolas","year":"2016","journal-title":"Biomedicines."},{"key":"B166","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jceh.2014.03.042","article-title":"Could stem cell therapy be the cure in liver cirrhosis?","volume":"5","author":"Irfan","year":"2015","journal-title":"J Clin Exp Hepatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2020.00149\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T22:01:14Z","timestamp":1615586474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2020.00149\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,5]]},"references-count":166,"alternative-id":["10.3389\/fmed.2020.00149"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2020.00149","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,5]]},"article-number":"149"}}